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Abstract
Background: A frequent manifestation of asthma, exercise-induced bronchoconstriction (EIB), occurs in 30–50% of
asthmatics and is characterized by increased release of inflammatory eicosanoids. The objective of this study was to identify
genes differentially expressed in EIB and to understand the function of these genes in the biology of asthma.
Methodology/Principal Findings: Genome-wide expression profiling of airway leukocytes and epithelial cells obtained by
induced sputum was conducted in two groups of subjects with asthma with and without EIB (n=7 per group), at baseline
and following exercise challenge. Based on the results of the gene expression study, additional comparisons were made
with a normal control group (n=10). Localization studies were conducted on epithelial brushings and biopsies from an
additional group of asthmatics with EIB (n=3). Genes related to epithelial repair and mast cell infiltration including b-
tryptase and carboxypeptidase A3 were upregulated by exercise challenge in the asthma group with EIB. A gene novel to
asthma pathogenesis, transglutaminase 2 (TGM2), was the most differentially expressed at baseline between the groups. In
vivo studies confirmed the increased expression of TGM2 in airway cells and airway lining fluid, and demonstrate that TGM2
is avidly expressed in the asthmatic airway epithelium. In vitro studies using recombinant human enzymes reveal that TGM2
augments the enzymatic activity of secreted phospholipase A2 (PLA2) group X (sPLA2-X), an enzyme recently implicated in
asthma pathogenesis.
Conclusions/Significance: This study found that TGM2, a mediator that is novel to asthma pathogenesis, is overexpressed
in asthmatic airways and functions to increase sPLA2-X enzymatic activity. Since PLA2 serves as the first rate-limiting step
leading to eicosanoid formation, these results suggest that TGM2 may be a key initiator of the airway inflammatory cascade
in asthma.
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Introduction
Although asthma is the most common chronic disease among
young adults, the molecular basis of asthma, especially related to
non-allergic stimuli remains poorly understood. A fundamental
barrier to understanding asthma is the heterogeneity of the
phenotype and characteristic pattern of inflammation in the lower
airways. One frequent manifestation of asthma is exercise-induced
bronchoconstriction (EIB), a syndrome in which a brief period of
exercise triggers airway narrowing lasting 30–90 min [1]. Cross-
sectional studies demonstrate that EIB occurs in a distinct group of
subjects with asthma, representing about 30–50% of all asthmatics
[2,3,4,5,6]. The severity of EIB is associated with other
manifestations of indirect airway hyperresponsiveness (AHR) to
hypertonic aerosols and adenosine [7].
We have previously demonstrated that there is a distinct pattern
of airway inflammation in asthmatics with EIB that is notable for
increased concentrations of inflammatory eicosanoids such as
cysteinyl leukotriene (CysLT)s and disrupted lower airway
epithelial cells in induced sputum [8]. Increased concentrations
of CysLTs have also been identified in exhaled breath condensate
of children with EIB [9]. We and others have shown that these
eicosanoids along with cellular products from mast cells and
eosinophils have a pivotal role in the pathogenesis of EIB, causing
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cell activation and the effects of mast cell products such as
histamine and CysLTs reduced the severity of EIB [12,13]. A key
regulator of eicosanoid release, secreted phospholipase A2 group X
(sPLA2-X), was recently shown to be increased in the airways of
asthmatics, and further increased after exercise challenge [14].
Deletion of the sPLA2-X gene in a murine model of asthma
inhibits development of airway inflammation, AHR, and struc-
tural remodeling [15].
Based on the distinct phenotypic characteristics and immuno-
pathology of EIB, we hypothesized that there are distinct
molecular pathways transcriptionally active in the airways of
asthmatics with EIB. To address this hypothesis, we identified two
groups of asthmatics with AHR to methacholine that were
discordant for severity of EIB, and compared gene expression in
airway leukocytes and epithelial cells in induced sputum between
the groups at baseline and then on a separate day following
exercise challenge. To assure that the results were reproducible,
we enrolled the subjects into initial and replication cohorts to
identify genes with consistent differences in gene expression, and
used a second method to identify differences in gene expression
based on the false discovery rate. Based on differences in gene
expression, we confirmed that transglutaminase 2 (TGM2) was
over-expressed in airway cells by quantitative PCR (qPCR), and
that the TGM2 protein is elevated in the airway lining fluid of
asthmatics with EIB relative to the asthma group without EIB.
Additional studies compared the expression and protein levels
between asthmatics and non-asthmatic controls, and defined the
distribution of TGM2 in the asthmatic airway epithelium. In vitro
studies revealed that recombinant human TGM2 causes a
sustained increase in the enzyme activity of recombinant human
sPLA2-X identifying a previously unknown mechanism of asthma
in which the increase in TGM2 in the airways may function to
amplify airway inflammation through eicosanoid generation.
Some of the results of this study have been previously reported
in the form of abstracts [16,17].
Methods
Detailed methods are provided in the online supporting
information (Text S1).
Study Subjects
The University of Washington Institutional Review Board approved
the study protocols, and written informed consent was obtained from
all participants. Subjects 18–59 years of age were recruited who had a
physician diagnosis of asthma for $1 year, and used only an inhaled
b2-agonist for asthma treatment. In accordance with ap r i o r idefinitions,
asthmatics with a methacholine PC20#4 mg/ml were identified with
$20% fall in FEV1 following exercise challenge (EIB
+ group) and
asthmatic controls without EIB were identified with #5% fall in FEV1
following exercise challenge (EIB
2 group). The first 3 subjects in each
group were enrolled into the initial cohort, and the subsequent subjects
were enrolled into the replication cohort.
Comparisons were also made to non-asthmatic subjects with
negative methacholine (PC20.8 mg/ml) and dry air exercise challenge
tests (,5% fall in FEV1 following exercise). Epithelial brushings and
endobronchial biopsies were obtained from an additional group
of subjects with asthma and EIB defined by a methacholine
PC20#4m g / m La n d$15% fall in FEV1following exercise challenge.
Study Protocol
Study subjects had spirometry and exercise challenge testing on
one day, and a methacholine challenge on a separate day to
determine eligibility for the study. The Seattle Asthma Severity
and Control Questionnaire (SASCQ) assessed asthma control
[18]. Eligible participants had 2 induced sputums conducted at
baseline and one induced sputum 30 min after exercise challenge,
each 2–10 days apart. Spirometry, exercise, and methacholine
challenges were conducted in accordance with American Thoracic
Society (ATS) standards [19,20]. Induced sputum was conducted
with 3% hypertonic saline via an ultrasonic nebulizer (DeVilbiss,
Somerset, PA, USA) [1].
RNA Isolation and Microarray Hybridization
The lower airway portion of the induced sputum was selected
using a transfer pipette and dispersed in dithiothreitol 0.1% at
20uC. The cell pellet was immediately treated with caotropic lysis
buffer and total RNA extracted. Biotin-labeled cRNA was
prepared from 2–5 mg RNA from each sample, and after
purification and fragmentation, hybridized with the Affymetrix
human U133A array in the initial cohort and the U133 Plus 2
array in the replication cohort (Affymetrix, Santa Clara, CA). All
the microarray data are MIAME compliant and have been
deposited in GEO (Gene Expression Omnibus) under accession
number GSE13785.
Confirmation of Differentially Expressed Genes by
Quantitative PCR, Western Blots, and
Immunohistochemistry
Differences in RNA levels of selected differentially expressed
genes were validated with qPCR using Taqman probes.[21]
Western blots measured differences in the level of TGM2 in
induced sputum supernatant and in epithelial lysates. TGM2 was
localized in endobronchial tissue by the indirect immunoperox-
idase technique using a rabbit polyclonal anti-TGM2 antibody.
TGM2-mediated Activation of sPLA2 Function
The ability of TGM2 to increase the enzymatic activity of
sPLA2s in vitro was tested by monitoring the release of free fatty
acid from [
3H]oleate-labeled E. coli membranes.[22] The
measurements of sPLA2 activity were conducted initially using
bovine pancreatic sPLA2 group 1B, and then recombinant human
sPLA2-X [23]. Studies were conducted with purified TGM2 from
guinea pig liver and then subsequently with rhTGM2. TGM2 was
pre-incubated at concentrations ranging from 0.1 to 50610
23 U/
reaction with sPLA2sa t3 7 uC for 15 min. Controls were
conducted using TGM2 at a concentration of 10610
23 U/
reaction after the enzyme was heat denatured at 100uC for 10 min
and with the active site of the enzyme saturated with N-
carbobenzoxy-Gln-Gly.
Statistical Analysis
The analytical approach was based on murine studies that
compared asthma phenotype [24,25] and on a human study
comparing gene expression before and after allergen challenge
[26]. The raw array data were normalized with GC Robust
Multiarray Algorithm (GCRMA) [27]. Differential gene expres-
sion between the groups in the initial data set and the replication
data set was determined with the linear models for microarray
data (limma) package and P-values were calculated with a
modified t-test in conjunction with an empirical Bayes method
to moderate the standard errors of the estimated log-fold changes
[28]. Two approaches were used to determine genes with
differential expression between the groups, and between condi-
tions (baseline and post-exercise). Genes with the most reproduc-
ible differential expression were identified by selecting genes in the
Airway Gene Expression in EIB
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then assessing the combined statistical significance using the
Fisher’s combined P method [29]. A Bonferroni’s correction
assuming a correlation among genes of 0.6 was used to establish
the P value cutoff. Based on the expression of 22,000 genes, a p
value,0.05, a false discovery rate of 10%, and fold change of 2
(Log2 ratio of 1), with a standard deviation of 0.3, a sample size of
3 subjects per group gives 80% power in each the initial and
replication cohorts [30]. The second approach was to determine
the overall statistical significance of the combined data sets using
Fisher’s combined P method and the q-value to account for
multiple testing based on a specified false discovery rate (FDR)
[31]. Simple averaging combined the fold change values from each
of the two platforms.
Results
Comparison of Asthma Phenotypes
We identified 15 subjects with asthma based on a methacholine
PC20#4 mg/ml, and enrolled 7 subjects who had EIB ($20% fall
in FEV1 post-exercise), and 7 subjects who did not have EIB (#5%
fall in FEV1 post-exercise) (Table 1). One additional subject was
excluded due to an indeterminate response (.5% but ,20% fall
in FEV1 post-exercise) to exercise challenge. There were no
differences in baseline lung function, asthma control, or response
to the administration of a bronchodilator between the two groups.
The reduction in FEV1 following exercise challenge was much
greater in the EIB
+ group as compared to the EIB
2 group
(P,0.001, Figure 1A) by definition. The EIB
+ group had a slightly
lower methacholine PC20 than the EIB
2 group (P=0.01),
resulting in a modest relationship between the maximum fall in
FEV1 after exercise challenge and the methacholine PC20
(r
2=0.43, P=0.01).
We isolated total RNA from leukocytes and epithelial cells in the
lower airway portion of induced sputum that was selected and
removed from salivary contamination.[32] The reproducibility of
cellular constituents from induced sputum was very high (Figure
S1 and Table S1). A comparison of induced sputum cellular
constituents revealed minimal differences in the concentrations of
leukocytes and epithelial cells between the groups (Figure S2 and
Tables S2, S3, S4, S5). One subject from each group had
insufficient RNA for the array analysis, but was included in the
qPCR analysis. RNA quality was verified by capillary gel
electrophoresis, and oligonucleotide microarrays were successfully
hybridized for all 24 samples (6 EIB
+ and 6 EIB
2, baseline and
post-exercise); however, one of the EIB
2 post-exercise microarrays
was excluded because of an unacceptably high normalized
unscaled standard errors metric as well as failure to meet the
manufacturer’s quality control guidelines for housekeeping control
probe signals which failed the threshold test.
Differential Gene Expression Between Asthmatic
Phenotypes
Gene expression in airway cells was analyzed between the two
phenotypically distinct groups of asthmatics at baseline, and
between the groups after exercise challenge. We used two methods
to identify genes with the most reproducible differential expression
between the groups. In the first method, we identified genes that
were differentially expressed in the initial cohort (first 3 subjects in
each group) and in the replication cohort (last three subjects in
each group), and narrowed the list of genes to those with Log2
[fold change] (Log2FC)$1.0 and P#0.05 in both cohorts. The
genes identified by this method represent genes with reproducible
differential expression in both cohorts as demonstrated by the
strong association between the magnitude of differential expression
identified in each cohort (r
2=0.40, P,0.0001, Figure 1B) and by
differences between the two groups demonstrated by a heatmap
showing the Log2FC relative to the average expression for each
gene in each individual of the two groups post-exercise (Figure 1C).
The combined statistical significance of these two sets was assessed,
and a conservative Bonferroni correction was applied to identify 1
gene with differential expression between the groups at baseline
and 19 genes with differential expression between the groups post-
exercise (Table 2). We also assessed differences between the groups
using the combined P value for the entire data set (Tables S6, S7).
Based on a false discovery rate (FDR) of 10%, 28 genes in the post-
exercise comparison were differentially expressed, including all 19
meeting the criteria for reproducible differential expression and 9





2 (n=7) P value
Age (yr)
Mean 27.7 32.7 0.33
Range 24–34 23–54





FEV1 (%) 88.069.4 85.969.6 0.68
FVC (%) 103.4612.6 99.468.8 0.50
FEV1/FVC 0.7260.06 0.7360.11 0.84
FEF25–75 (%) 58.669.6 64.0613.0 0.39
Post Bronchodilator
D FEV1 (%) 7.163.5 8.965.7 0.51
D FVC (%) 20.461.8 20.061.72 0.69
D FEF25–75 (%) 22.867.1 20.167.1 0.49
Exercise-induced Bronchoconstriction
Maximum Decrease in FEV1 234.161.2 21.262.0 ,0.001
Area Under FEV1 Curve
{ 2749.76288.4 95.7675.7 ,0.001
Direct Bronchial Hyperresponsiveness
PC20 Methacholine
{ 0.2 (0.1–0.4) 1.0 (0.4–2.5) 0.01
Asthma Control
¥
Nocturnal Symptoms 0.060.0 0.260.4 0.36
Daytime Symptoms 2.261.6 1.260.8 0.20
Activity Limitation 0.460.6 0.760.8 0.55
Asthma Exacerbations 1.061.4 0.761.2 0.68
Bronchodilator Use 1.662.1 1.362.0 0.83
SASCQ Summary Score 5.265.2 4.063.3 0.65
Asthma-free Days 19.269.7 24.264.6 0.29
Acute Asthma Visits 0.060.0 0.060.0 NS
Non-acute Asthma Visits 0.460.5 1.261.2 0.21
*Values reported are mean6standard deviation unless otherwise specified.
{Area under the FEV1 curve over the first 30 min after exercise (% change*min).
{Value represent the geometric mean (95% confidence interval). The P value is
for the log-transformed value.
¥Asthma control questions are from the Seattle Asthma Severity and Control
Questionnaire (SASCQ) on a 0–5 point scale.
doi:10.1371/journal.pone.0008583.t001
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PFN2, IQCG, EFHC1, SERPINB2, and an expressed sequence
tag (AV720803). Differences in the expression of 10 of these genes
were confirmed by qPCR using samples from all individuals in
each group, demonstrating a high degree of reproducibility by
array or qPCR methods (Figure 1D).
Genes Expression Response to Exercise Challenge
Because the bronchoconstrictor response to exercise challenge
is a distinguishing feature of the EIB phenotype, the gene
expression response to exercise challenge was assessed. We
identified genes transcriptionally activated by exercise challenge
in the initial cohort and replication cohorts of EIB
+ subjects, and
Figure 1. Comparison of lung function and gene expression between asthmatics with EIB and an asthmatic control group without
EIB. The severity of EIB was markedly greater in the EIB
+ group (A). Genes that were increased in the EIB
+ group relative to the EIB
2 group post-
exercise were consistently differentially expressed in the initial and replication cohorts as shown by the strong association between differences in
gene expression in each cohort (B). A heatmap of these genes shows the Log2FC relative to the average expression for each gene in each individual
of the two groups post-exercise (C). The fold difference in gene expression between the groups post-exercise identified by the microarray platform
was similarly demonstrated by qPCR (D). Within the EIB
+ group, genes that increased in response to exercise challenge were consistently increased in
the initial and replication cohorts (E). A heatmap of these genes shows the Log2FC relative to the average expression for each gene in each individual
of the EIB
+ cohort (F). The fold increase in gene expression in response to exercise challenge by the microarray platform was similarly demonstrated
by qPCR with the exception of CLCA1 and KLK11 (G). To visualize the differences in the pattern of gene expression, differences in gene expression
between the groups at baseline are plotted against the change in gene expression with exercise challenge in the EIB
+ group (H).
doi:10.1371/journal.pone.0008583.g001
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expression in both cohorts as demonstrated by the strong
association of the differentially expressed genes in each cohort
(r
2=0.54, P,0.0001, Figure 1E), and by differences between the
baseline and post-exercise conditions demonstrated by a heatmap
showing the Log2FC relative to the average expression for each
gene in each individual of the EIB
+ cohort (Figure 1F). After
applying a Bonferroni correction, 9 genes had increased
expression and no genes had decreased expression following
exercise challenge in the EIB
+ group (Table 3). We also assessed
changes in gene expression after exercise challenge using the
combined P value for the EIB
+ phenotype (Table S8). Based on a
FDR of 10%, 8 genes had increased expression following exercise
challenge in the EIB
+ group, including 3 additional genes
CLCA2, FCGBP, and CST1 not observed in our initial selection
algorithm. We confirmed exercise-induced increases in expres-
sion of 7 of these genes (TFF3, TPSAB, CPA3, KLK11,
TSPAN8, AGR2, and SLPI) by qPCR (Figure 1G). In the
EIB
2 group, no gene met either criterion for change in
expression in response to exercise challenge.
We also evaluated in the change in gene expression in response
to challenge in the EIB
+ group relative to the change in expression
in the EIB
2 group (i.e. interaction effect, Table S9) and found that
7 genes TPSB2, CLCA1, FCGBP, CST1, TPSAB1, CPA3, and
Table 2. Genes with differential increased expression in the EIB
+ group.
GenBank Log2FC P value Symbol Description
Baseline
BC003551 2.04 0.0002 TGM2 Transglutaminase 2
Post-exercise
NM_003226 4.80 0.0000 TFF3 Trefoil factor 3
AF127036 5.23 0.0000 CLCA1 Chloride channel, Ca
2+-activated, member 1
NM_024164 3.50 0.0000 TPSB2 Tryptase b2
NM_001898 3.87 0.0000 CST1 Cystatin SN
NM_003890 2.85 0.0000 FCGBP Fc fragment of IgG-binding protein
NM_001870 4.70 0.0000 CPA3 Carboxypeptidase A3 (mast cell)
AF206667 3.94 0.0000 TPSAB1 Tryptase a/b1
NM_006853 2.12 0.0000 KLK11 Kallikrein-related peptidase 11
NM_004616 4.25 0.0000 TSPAN8 Tetraspanin 8
AF088867 4.69 0.0000 AGR2 Anterior gradient homolog 2
AI743792 2.06 0.0000 ST6GAL1 ST6 b-galactosamide a-2,6-sialyltransferase 1
NM_003064 3.03 0.0001 SLPI Secretory leukocyte peptidase inhibitor
AI521646 4.76 0.0002 MUC5AC Mucin 5AC, oligomeric mucus/gel-forming
NM_016140 3.02 0.0002 CGI-38 Brain-specific protein
NM_015180 1.73 0.0002 SYNE2 Spectrin repeat-containing, nuclear envelope 2
NM_015717 1.93 0.0003 CD207 CD207, langerin
NM_001828 5.34 0.0003 CLC Charcot-Leyden crystal protein
AK000168 4.03 0.0006 CD24 CD24
AF133425 3.97 0.0007 TSPAN1 Tetraspanin 1
doi:10.1371/journal.pone.0008583.t002
Table 3. Genes in EIB
+ group with increased expression in response to exercise challenge.
GenBank Log2FC P value Symbol Description
NM_024164 3.69 0.0000 TPSB2 Tryptase b2
AF127036 4.46 0.0000 CLCA1 Chloride channel, Ca
2+-activated, member 1
NM_003226 3.48 0.0000 TFF3 Trefoil factor 3 (intestinal)
NM_003294 3.63 0.0000 TPSAB1 Tryptase a/b1
NM_001870 4.46 0.0000 CPA3 Carboxypeptidase A3 (mast cell)
NM_006853 1.58 0.0002 KLK11 Kallikrein-related peptidase 11
NM_015717 1.90 0.0003 CD207 CD207 molecule, langerin
AI521646 4.31 0.0004 MUC5AC Mucin 5AC, oligomeric mucus/gel-forming
NM_004616 2.96 0.0007 TSPAN8 Tetraspanin 8
doi:10.1371/journal.pone.0008583.t003
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reproducibility criteria, and an additional gene CLCA2 based on
the FDR.
To visualize the differences in the pattern of gene expression,
differences in gene expression between the groups at baseline are
plotted against the change in gene expression with exercise
challenge in the EIB
+ group (Figure 1H). Only transglutaminase 2
(TGM2) was differentially expressed at baseline, while other genes
including the mast cell proteases were not differentially expressed
at baseline, but had a marked increase following exercise
challenge. Other genes such as trefoil factor 3 (TFF3) had modest
increase in expression at baseline and further increase after
exercise challenge.
Confirmation of Differentially Expressed Genes in the
Airways
We focused on TGM2 because it was the only gene that was
differentially expressed between the groups at baseline. Because
the difference in TGM2 expression between the two asthma
groups was modest in magnitude, we also assessed the expression
of TGM2 by qPCR in a non-asthmatic control group demon-
strating that the expression of TGM2 was increased in both
asthma groups relative to the non-asthmatic group, and that it was
further increased in asthmatics with the EIB
+ phenotype
(Figure 2A). The 85 kDa TGM2 protein was essentially undetect-
able from the non-asthmatic group, but measurable in most of the
asthmatic samples, and increased in the EIB
+ asthmatic group
Figure 2. Comparison of TGM2 levels in the airways and in vitro function of TGM2 in the activation of secreted PLA2 activity. The
gene expression of TGM2 by qPCR in airway cells was increased in both asthma groups relative to non-asthmatic controls, and the expression was
higher in the EIB
+ group (A). TGM2 was not detected in induced sputum supernatant from non-asthmatic controls, but was elevated in asthmatics,
especially in the EIB
+ group (B). The bands from one of two Western blots used to quantify the levels of TGM2 in induced sputum supernatant are
shown in the panel, with lanes 1–5 representing EIB
+ asthmatics, lanes 6–10 representing EIB
2 asthmatics, and lanes 11–15 normal controls (C). A
Western blot of epithelial brushings from asthmatics demonstrates higher levels in the epithelium from asthmatics relative to non-asthmatic controls
(D). In the blot, the first lane is recombinant human TGM2 (rhTGM2), lanes 3 and 4 are epithelial lysates from 2 different EIB
+ asthmatics, and lanes 5
and 6 are epithelial lysates from 2 different normal controls. Asthmatic epithelial cells from an EIB
+ asthmatic in primary culture shown in lanes 8 and
9 also strongly express TGM2. Immunostaining for TGM2 in airway biopsies from an EIB
+ asthmatic demonstrates immunostaining in the airway
epithelium for TGM2 (406, scale bar is 50 mm) (E). Pre-incubation of recombinant human sPLA2-X with purified TGM2 from guinea pig liver (F) or with
recombinant human TGM2 (G) causes an increase in the PLA2 activity of the sPLA2-X enzyme. Denaturing the TGM2 with heat (boiled) or inhibiting
the activity of the enzyme by saturating the enzyme with N-carbobenzoxy-Gln-Gly (Inh) demonstrate that the in vitro findings are due to the
enzymatic activity of TGM2.
doi:10.1371/journal.pone.0008583.g002
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measure a portion of the gene that is common to both the full-
length gene and the recently described splice variant [33]. In
epithelial brushings from asthmatics with EIB, the level of TGM2
was increased relative to non-asthmatic controls, and the level of
TGM2 was markedly increased in airway epithelial cells in
primary culture from an EIB
+ asthmatic individual (Figure 2D).
Immunohistochemistry of airway biopsies taken from conducting
airways of 3 EIB
+ asthmatic individuals demonstrated strong
immunostaining for TGM2 in the epithelial layer (Figure 2E and
Figure S3)
Effects of Transglutaminase 2 on Native and
Recombinant sPLA2 Activity
The ability of TGM2 to increase the enzymatic activity of
sPLA2-X in vitro was tested by monitoring the release of free fatty
acid from [
3H]oleate-labeled E. coli membranes [22]. Recombi-
nant human sPLA2-X was generated in E. coli, purified and
refolded to the active enzyme [23]. The initial experiments were
conducted with purified TGM2 from guinea pig liver, and then
subsequently with recombinant human TGM2. Pre-incubation of
sPLA2-X at 37uC for 15 min with guinea pig TGM2 caused a
concentration dependent increase in the enzyme activity of sPLA2-
X (Figure 2F). Similarly, the human recombinant TGM2 caused a
concentration-dependent increase in sPLA2-X activity (Figure 2G).
To further demonstrate that the increase in sPLA2-X was due to
the enzymatic activity of the TGM2, we found that heat
denaturing the TGM2 enzyme prior to the experiment, or
saturating the active site of the enzyme with N-carbobenzoxy-Gln-
Gly inhibited the activation of sPLA2-X (Figures 2F–G).
Discussion
Relatively little is known about the immunological basis of
indirect AHR, an aspect of asthma that is manifested by the
presence of airway narrowing triggered by exercise, hypertonic
aerosols, cold air and adenosine [7]. In a recent large longitudinal
study of children, cold-air AHR was one of the strongest predictors
of persistent asthma in adulthood [34]. In the present study, we
enrolled subjects with a rigorous diagnosis of asthma, and
identified subjects with and without EIB, a syndrome character-
ized by an abnormal airway epithelium and increased concentra-
tions of inflammatory eicosanoids in the airways [8]. Through
analysis of airway gene expression before and after exercise
challenge in these distinct groups, we found that genes related to
epithelial repair and mast cell infiltration are increased in
asthmatics with EIB, and that TGM2 is the most differentially
expressed between the groups at baseline. We confirmed that the
TGM2 protein is increased in airway cells and airway lining fluid
in the EIB positive group, and that both asthma groups have
increased levels relative to a non-asthmatic control group. We also
found that the TGM2 protein is avidly expressed in the epithelium
of the EIB positive asthmatics. Further, TGM2 causes a sustained
increase in sPLA2-X activity, identifying a novel mechanism by
which increased expression of TGM2 may serve to amplify airway
inflammation in asthma.
The present study adds to an accumulating body of evidence
from gene-array studies that genes such as CLCA1 [35,36],
SerpineB2 [26,36,37], MUC5AC [35,37], AGR2 [35], CPA3
[36,37], and tryptase [36,37] are overexpressed in asthma, and
suggests that these genes are more transcriptionally active in the
EIB phenotype. A further advance in the present study was the
evaluation of gene expression in response to exercise challenge that
induces acute asthma in susceptible subjects demonstrating that
several of the genes are transcriptionally activated during acute
asthma. We chose an early time point following challenge in this
study to minimize secondary transcriptional activation in response
to the release of mediators in the airways. Several common gene
expression programs emerge with increased expression in the EIB
phenotype notable for genes related to epithelial repair and
differentiation including TFF3, TGM2, TSPN8, TSPN1, SLPI,
and CD24, as well as regulation of epithelial lining fluid and mucin
production including CLCA1, MUC5AC, and AGR2. In
addition, proteases including the mast cells proteases TPSB2 and
CPA3 as well as KLK11 and protease inhibitors such CST1 and
SLPI are notably increased in the EIB positive group. These
findings provide new insights into the pathogenesis of acute
asthma, and suggest that genes related to epithelial repair are more
active in asthma, and are particularly active in the EIB phenotype.
Increased transcription of mast cell proteases tryptase and
CPA3 in the EIB
+ group following exercise challenge adds
additional evidence that mast cell activation plays an important
role in the pathophysiology of EIB. We have previously
demonstrated mast cell activation following exercise challenge in
EIB as evidenced by release of mast cell-specific mediators
histamine and tryptase [1]. A notable finding in the present study
is that CPA3, a secretory granule metalloexopeptidase that is
predominantly expressed in mast cells of the MCTC type was
increased along with tryptase. Mast cells are functionally divided
into MCT and MCTC types based on the composition of their
secretory granules that contain tryptase in both types of cells, but
with the addition of chymase, carboxypeptidase A3, and cathepsin
G in the MCTC type. Increased expression of both tryptase and
CPA3 was also recently noted in the airway epithelium in asthma
[36], suggesting that the expression of these proteases are
increased in asthma, and further increased in patients with EIB.
We found that TGM2 gene expression and secreted protein are
increased in the airways of subjects with asthma, and further
increased in the EIB
+ phenotype. Although TGM2 has been
implicated in a number of inflammatory diseases, and has been
shown to be upregulated by retinoic acid in transformed airway
epithelial cells [38], it has not been previously implicated in asthma.
The TGM2 gene is located on chromosome 20q11.2-12 near a
clusterofgenesrelatedtoepithelialbarrierfunctionincloseproximity
to a region linked to both atopic dermatitis and asthma [39]. Two of
the other differentially expressed genes in the present study, SLPI and
CST1, are also located in this region of chromosome 20. TGM2 is a
calcium-dependent enzyme that modifies protein structure through
the transfer of an acyl group from glutamine to lysine or free amines
resulting in a new inter- or intra-molecular amidic cross-link that may
directly alter the enzyme activity of sPLA2 [40]. In studying the
function of TGM2 in asthma, we demonstrated that TGM2
enzymatically modifies sPLA2-X leading to a substantial increase in
the PLA2 activity of the enzyme. This finding has strong implications
for the pathophysiology of asthma since PLA2 catalyzes the first rate-
limiting step leading to eicosanoids such as CysLTs that play an
important role in asthma. Our prior research has found that EIB
+
asthmatics have increased levels of CysLTs and CysLT/PGE2 ratio
relative to asthmatics without EIB [8] and elevated levels of
15SHETE relative to non-asthmatic controls [14]. Although there
are 9 functional human sPLA2s [41], we focused on the functional
alteration of sPLA2- Xb e c a u s ew eh a v er e c e n t l yf o u n dt h a ts P L A 2-X
is increased in the airways of asthmatics, and may be involved in
eicosanoid generation in the airways post-exercise challenge [14].
Further, deletion of the sPLA2-X gene in a murine model of asthma
markedly inhibits the development of airway inflammation, AHR,
Th2 cytokine production, and structural remodeling [15]. In prior
investigations, TMG2 from guinea pig liver has been shown to
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inhibitors of TGM2 and sPLA2 reduced ocular inflammation in a
rabbit model of allergen-induced conjunctivitis [40]. In addition to
regulating the release of free arachidonate, sPLA2s are also involved
in the generation of lysophospholipids and the degradation of
surfactant phospholipids implicated in asthma pathogenesis [41]. In
addition to effects on eicosanoid metabolism TGM2 also activates the
transcription factor NFkB that is broadlyimplicated in the generation
of pro-inflammatory cytokines in asthma and other inflammatory
diseases, and induces iNOS via NFkB [42].
In summary, we have identified novel mediators of asthma using
genome-wide expression profiling in phenotypically distinct groups
of asthmatics. We found that processes related to epithelial repair
and mast cell infiltration were increased in the asthma group that
had EIB. Functional analyses demonstrated TGM2 causes a
sustained increase in sPLA2-X activity. Because PLA2 is an
enzyme that catalyses the first rate-limiting step leading to
eicosanoids, and specifically sPLA2-X has recently been identified
as a potential mediator of AHR in a murine model of asthma and
in human subjects with asthma, these findings may reveal a novel
mechanism that functionally serves to amplify airway inflamma-
tion through the generation of inflammatory eicosanoids known to
be increased in the EIB phenotype.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0008583.s001 (0.12 MB
DOC)
Figure S1 Bland-Altman plots for the reproducibility of the
concentration of leukocytes and epithelial cells in induced sputum.
The plots represent the concentration of lower airway cells (A),
and percentage of eosinophils (B), lymphocytes (C), macrophages
(D), neutrophils (E), and columnar epithelial cells (F) in induced
sputum. The Bland-Altman plot summarizes the difference in the
measure between two visits versus the average value of the
measure for the two visits for each subject. Each plot shows the
overall average difference (solid line)62 standard deviations
(dashed line). These results demonstrate that the induced sputum
cell counts are reproducible because the individual points on the
Bland-Altman plot are randomly scattered around the overall
average difference, and most points fall within 2 standard
deviations of the overall average difference.
Found at: doi:10.1371/journal.pone.0008583.s002 (0.36 MB TIF)
Figure S2 Comparison of the concentrations of inflammatory
and epithelial cells in induced sputum before and after exercise
challenge. The baseline and post-exercise induced sputum tests
were conducted on average 6.5 days apart. There were no
significant changes in the concentrations of eosinophils (Eos),
lymphocytes (Lymph), macrophages (Mac), and neutrophils
(PMN) in induced sputum in EIB+ asthmatics (A) or a group of
EIB- asthmatic controls (B). The concentration of epithelial cells
(Epi) increased significantly in the EIB+ group, and a similar trend
occurred in the EIB- control group.
Found at: doi:10.1371/journal.pone.0008583.s003 (0.58 MB TIF)
Figure S3 Immunostaining for TGM2 in biopsies of the airway
epithelium of EIB+ asthmatics. Immunostaining for TGM2 is
strong in the airway epithelium and surrounding matrix of
endobronchial biopsy from an EIB+ asthmatic (A). Non-specific
immunostaining was not observed using an isotype control
antibody (B).
Found at: doi:10.1371/journal.pone.0008583.s004 (3.20 MB TIF)
Table S1 Reproducibility of cellular components of induced
sputum on 2 separate visits
Found at: doi:10.1371/journal.pone.0008583.s005 (0.03 MB
DOC)
Table S2 Baseline differences in selected induced sputum*
Found at: doi:10.1371/journal.pone.0008583.s006 (0.05 MB
DOC)
Table S3 Post-exercise Differences in Selected Induced Spu-
tum*
Found at: doi:10.1371/journal.pone.0008583.s007 (0.05 MB
DOC)
Table S4 Regression analysis of differences in selected induced
sputum at baseline*
Found at: doi:10.1371/journal.pone.0008583.s008 (0.04 MB
DOC)
Table S5 Regression analysis of differences in selected induced
sputum post-exercise*
Found at: doi:10.1371/journal.pone.0008583.s009 (0.04 MB
DOC)
Table S6 Genes with increased expression in EIB+ group
relative to EIB- group at baseline (Log2FC.1, P,0.05)
Found at: doi:10.1371/journal.pone.0008583.s010 (0.04 MB
DOC)
Table S7 Genes with differential expression in EIB+ group
relative to EIB- group post exercise (Log2FC.1, P,0.05)
Found at: doi:10.1371/journal.pone.0008583.s011 (0.13 MB
DOC)
Table S8 Genes with change in expression after exercise
challenge in the EIB+ group (Log2FC.1, P,0.05)
Found at: doi:10.1371/journal.pone.0008583.s012 (0.08 MB
DOC)
Table S9 Genes with changes in expression after exercise
challenge (post-exercise minus baseline) in the EIB+ group relative
to EIB- group (Log2FC.1, P,0.05)
Found at: doi:10.1371/journal.pone.0008583.s013 (0.06 MB
DOC)
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